Press & News

2018-09-24

Solna, Sweden, September 24, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing...[read more]

Financial Calendar

2018

August
Interim Report Q2 – August 23, 2018

November
Interim Report Q3 – November 16, 2018

Affibodys latest Press releases

2018-09-24

New HER2 PET Study Uses Affibody’s ABY-025 Tracer to Individualize Breast Cancer Treatment

Solna, Sweden, September 24, 2018. Affibody AB (“Affibody”), a clinical stage biopharmaceutical company developing a portfolio of innovative drug...[read more]

Press & News

Affibody in short

Affibody is a Swedish biotech company focused on developing next generation biopharmaceuticals based on its unique proprietary technology platforms: Affibody® molecules and Albumod™.

About Affibody

Upcoming reports Financial calendar

Interim Report Q2 (August 23, 2018)

Investor information